• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

AngioSoma taps new CEO

December 9, 2016 By Sarah Faulkner

AngioSoma taps new CEOAngioSoma (OTCQB:SOAN) said today that it named Ken Stephenson to the Montgomery, Texas-based company’s corner office. Alexanderia Blankenship will now serve as chief operating officer and executive VP.

Stephenson has worked with hospitals, health insurance organizations and physician’s offices throughout Texas, according to the company. He previously helped set up practices for interventional radiologists and cardiologists, a perspective that AngioSoma said it hoped will help bridge the gap between its products, current standard-of-care treatments and insurance reimbursement processes.

“Working with Ken for the last month and a half, providing him due diligence, and working on AngioSoma, Inc.’s operational plan has been a pleasure,” Blankenship said in prepared remarks. I believe that Ken will be able to accelerate the company’s ability to secure funding, and bring our ‘end to end’ solution to market.”

AngioSoma touts its ‘end to end’ solution as guidance for interventional radiologists, cardiologists and internal medicine physicians regarding interventional options prior to infarction or critical limb ischemic events.

The company is also developing a pharmaceutical stabilization product, Liprostin, for the treatment of peripheral artery disease. Liprostin has completed phase I and II clinical trials and will soon enter a phase III trial, according to AngioSoma. For long-term treatment of chronic cardiovascular disease, the company has developed its Transdermal PGE-1 patch to deliver PGE-1 or Liprostin through the skin.

Filed Under: Cardiovascular, Clinical Trials, Personnel, Pharmaceuticals, Wall Street Beat Tagged With: AngioSoma

IN CASE YOU MISSED IT

  • Another BD Alaris infusion pump recall is Class I
  • Amgen completes $1.9B acquisition of Five Prime Therapeutics
  • Oncopeptides seeks EU marketing authorization for multiple myeloma treatment
  • Horizon touts data from trials for thyroid eye disease infusion treatment
  • Genentech touts study results for spinal muscular atrophy drug in babies

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Footer

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
Medical Tubing + Extrusion

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS